CT-388

CT-388
Identifiers
CAS Number

CT-388 is a "biased" dual GLP-1 and GIP receptor agonist/modulator with minimal to no beta-arrestin coupling at either receptor and is designed to be administered as once weekly subcutaneous injection.[1] In a 24-week trial participants averaged 18.8 percent placebo adjusted weight loss. The drug is developed by Roche/Genentech.[2][3][4]

References

  1. ^ Chakravarthy, Manu; ArgüElles-Tello, Federico A.; Sun, Ana Liza A.; Elliott, Michael; Acosta, Luis; Rankin, Jonathon E.; Hansen, Stig K. (20 June 2023). "75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four Weeks in Overweight and Obese Adults". Diabetes. 72 (Supplement_1). doi:10.2337/db23-75-LB.
  2. ^ "Genentech: Press Releases | Wednesday, May 15, 2024". www.gene.com.
  3. ^ Constantino, Annika Kim (16 May 2024). "Roche says weight loss drug shows promising results in early trial". CNBC. Retrieved 27 May 2024.
  4. ^ "Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity". Roche: Press Releases. May 16, 2024. Retrieved 2024-07-26.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.